TY  - GEN
AU  - Sebastian,Martin
AU  - Schröder,Andreas
AU  - Scheel,Birgit
AU  - Hong,Henoch S
AU  - Muth,Anke
AU  - von Boehmer,Lotta
AU  - Zippelius,Alfred
AU  - Mayer,Frank
AU  - Reck,Martin
AU  - Atanackovic,Djordje
AU  - Thomas,Michael
AU  - Schneller,Folker
AU  - Stöhlmacher,Jan
AU  - Bernhard,Helga
AU  - Gröschel,Andreas
AU  - Lander,Thomas
AU  - Probst,Jochen
AU  - Strack,Tanja
AU  - Wiegand,Volker
AU  - Gnad-Vogt,Ulrike
AU  - Kallen,Karl-Josef
AU  - Hoerr,Ingmar
AU  - von der Muelbe,Florian
AU  - Fotin-Mleczek,Mariola
AU  - Knuth,Alexander
AU  - Koch,Sven D
TI  - A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer
SN  - 1432-0851
PY  - 2019///0522
KW  - Aged
KW  - Aged, 80 and over
KW  - Antigens, Neoplasm
KW  - genetics
KW  - B-Lymphocytes
KW  - immunology
KW  - Cancer Vaccines
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Cells, Cultured
KW  - Female
KW  - Humans
KW  - Immunotherapy
KW  - adverse effects
KW  - Injection Site Reaction
KW  - etiology
KW  - Lung Neoplasms
KW  - Lymphocyte Activation
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - RNA, Messenger
KW  - administration & dosage
KW  - Survival Analysis
KW  - T-Lymphocytes
N1  - Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
UR  - https://doi.org/10.1007/s00262-019-02315-x
ER  -